<DOC>
	<DOC>NCT00206687</DOC>
	<brief_summary>The purpose of the study is to explore the safety, tolerability and efficacy of Spheramine (cultured human retinal pigment epithelial cells on microcarriers) in Parkinson's Disease patients with advanced disease who have insufficient symptom control by optimum oral medication. Patients are randomized to receive Spheramine injections into both hemispheres or a sham surgical procedure in a ratio of 1:1. A three month pretreatment period must be completed prior to surgery. Time to endpoint is 24 months.</brief_summary>
	<brief_title>STEPS Trial - Spheramine Safety and Efficacy Study</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. and Schering AG, Germany.Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors of the trial.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Advanced Parkinson's disease for at least 5 years Good response to Ldopa Age 30 to 70 years Optimum oral therapy Tremor only Dementia Very severe dyskinesia Previous brain surgery including deep brain stimulation Malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>